150 related articles for article (PubMed ID: 10516800)
1. Effects of typical antipsychotic drugs and risperidone on the quality of sleep in patients with schizophrenia: a pilot study.
Dursun SM; Patel JK; Burke JG; Reveley MA
J Psychiatry Neurosci; 1999 Sep; 24(4):333-7. PubMed ID: 10516800
[TBL] [Abstract][Full Text] [Related]
2. A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition.
Akdede BB; Anil Yağcioğlu AE; Alptekin K; Turgut TI; Tümüklü M; Yazici MK; Jayathilake K; Tunca Z; Göğüş A; Meltzer HY
J Clin Psychiatry; 2006 Dec; 67(12):1912-9. PubMed ID: 17194269
[TBL] [Abstract][Full Text] [Related]
3. Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone.
Yamanouchi Y; Iwata N; Suzuki T; Kitajima T; Ikeda M; Ozaki N
Pharmacogenomics J; 2003; 3(6):356-61. PubMed ID: 14610521
[TBL] [Abstract][Full Text] [Related]
4. [Effects of risperidone on polysomnography in patients with first-episode schizophrenia].
Chen XS; Zhang MD; Lou FY; Wang HX; Wang JJ; Liang JH; Chen C; Chen XW; Liu L; Gao CY; Liu P; Liu XW
Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(35):2467-70. PubMed ID: 17156674
[TBL] [Abstract][Full Text] [Related]
5. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
Houthoofd SA; Morrens M; Sabbe BG
Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
[TBL] [Abstract][Full Text] [Related]
6. Basal ganglia volumes in drug-naive first-episode schizophrenia patients before and after short-term treatment with either a typical or an atypical antipsychotic drug.
Glenthoj A; Glenthoj BY; Mackeprang T; Pagsberg AK; Hemmingsen RP; Jernigan TL; Baaré WF
Psychiatry Res; 2007 Apr; 154(3):199-208. PubMed ID: 17360162
[TBL] [Abstract][Full Text] [Related]
7. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
8. Acute risperidone treatment did not increase daily cigarette consumption or plasma levels of cotinine and caffeine: a pilot study.
Yoshimura R; Kakihara S; Umene-Nakano W; Sugita A; Hori H; Ueda N; Nakamura J
Hum Psychopharmacol; 2008 Jun; 23(4):327-32. PubMed ID: 18273830
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
[TBL] [Abstract][Full Text] [Related]
10. Risperidone-related weight gain: genetic and nongenetic predictors.
Lane HY; Liu YC; Huang CL; Chang YC; Wu PL; Lu CT; Chang WH
J Clin Psychopharmacol; 2006 Apr; 26(2):128-34. PubMed ID: 16633140
[TBL] [Abstract][Full Text] [Related]
11. [Social cognition and atypical antipsychotic agents in the treatment of persons with schizophrenia: preliminary data from a naturalistic study].
Mazza M; Tozzini C; Giosué P; De Risio A; Palmucci M; Roncone R; Casacchia M
Clin Ter; 2003; 154(2):79-83. PubMed ID: 12856365
[TBL] [Abstract][Full Text] [Related]
12. Association between plasma nitric oxide metabolites levels and negative symptoms of schizophrenia: a pilot study.
Nakano Y; Yoshimura R; Nakano H; Ikenouchi-Sugita A; Hori H; Umene-Nakano W; Ueda N; Nakamura J
Hum Psychopharmacol; 2010 Mar; 25(2):139-44. PubMed ID: 20196178
[TBL] [Abstract][Full Text] [Related]
13. Risperidone in the management of violent, treatment-resistant schizophrenics hospitalized in a maximum security forensic facility.
Beck NC; Greenfield SR; Gotham H; Menditto AA; Stuve P; Hemme CA
J Am Acad Psychiatry Law; 1997; 25(4):461-8. PubMed ID: 9460034
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics.
Lane HY; Lee CC; Liu YC; Chang WH
Pharmacogenomics; 2005 Mar; 6(2):139-49. PubMed ID: 15882132
[TBL] [Abstract][Full Text] [Related]
15. Reemergence of positive symptoms after initial response to risperidone.
Cung DD; Stimmel GL
Pharmacotherapy; 1997; 17(2):383-6. PubMed ID: 9085334
[TBL] [Abstract][Full Text] [Related]
16. Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia.
Ikeda M; Yamanouchi Y; Kinoshita Y; Kitajima T; Yoshimura R; Hashimoto S; O'Donovan MC; Nakamura J; Ozaki N; Iwata N
Pharmacogenomics; 2008 Oct; 9(10):1437-43. PubMed ID: 18855532
[TBL] [Abstract][Full Text] [Related]
17. Antipsychotic treatment and weight gain: does risperidone behave differently in Pakistani psychiatric patients?
Iqbal SP; Khan RA; Ahmer S
J Ayub Med Coll Abbottabad; 2011; 23(1):66-9. PubMed ID: 22830150
[TBL] [Abstract][Full Text] [Related]
18. Comments on 'The effect of risperidone on D-amino acid oxidase activity as a hypothesis for a novel mechanism of action in the treatment of schizophrenia'.
Hashimoto K
J Psychopharmacol; 2010 Jul; 24(7):1133-4. PubMed ID: 19939869
[No Abstract] [Full Text] [Related]
19. Serotonin-mediated increase in cytosolic [Ca++] in platelets of risperidone-treated schizophrenia patients.
Ereshefsky L; Riesenman C; True JE; Javors M
Psychopharmacol Bull; 1996; 32(1):101-6. PubMed ID: 8927657
[TBL] [Abstract][Full Text] [Related]
20. Sleep quality and architecture in quetiapine, risperidone, or never-treated schizophrenia patients.
Keshavan MS; Prasad KM; Montrose DM; Miewald JM; Kupfer DJ
J Clin Psychopharmacol; 2007 Dec; 27(6):703-5. PubMed ID: 18004141
[No Abstract] [Full Text] [Related]
[Next] [New Search]
